Neurizon Therapeutics has received ethics approval for an Australia-based Phase 1 clinical trial that will test an oral liquid…
Articles by Andrea Lobo, PhD
EverythingALS has launched a new online tool called SAVA AI that uses artificial intelligence to instantly match people with…
The U.S. Food and Drug Administration (FDA) has granted fast-track designation to tazbentetol, an experimental oral therapy being developed by…
Acurastem has received $7.5 million in funding from the California Institute for Regenerative Medicine (CIRM) to advance AS-241, its…
Vectory Therapeutics has been given a green light to expand its first-in-human clinical trial of VTx-002, its treatment candidate…
RAG-17, an experimental treatment Ractigen Therapeutics is developing for people with amyotrophic lateral sclerosis (ALS) who carry a…
Maintaining body weight after starting enteral nutrition, or tube feeding, may help extend survival in people with amyotrophic lateral…
Up to six people with advanced amyotrophic lateral sclerosis (ALS) will be treated with Trethera’s experimental therapy TRE-515…
Insitro and Bristol Myers Squibb have expanded their ongoing collaboration to develop new treatments for amyotrophic lateral…
The first patient has been dosed in a small clinical trial in Australia that’s testing CTx1000, Celosia Therapeutics’ experimental…